"Whether treating patients with complex cancers or those with benign tumors, I am dedicated to providing each patient with the absolute best possible outcome. Attaining this high standard requires that our team operate at the very leading edge of medicine while still providing patients with the same care we would provide members of our very own family."


Jeffrey J. Houlton, M.D., joined the department in 2014. He is currently an associate professor and is also a member of the Head & Neck Surgery Division.

Dr. Houlton was raised in Houston, Texas, and graduated medical school at the University of Texas Medical Branch with high honors. In medical school he was inducted into the prestigious Alpha Omega Alpha Honor Society. He underwent residency training in otolaryngology - head and neck surgery at the University of Cincinnati where he developed special interest in the treatment of head and neck cancer patients and their complex reconstructive needs. This led him to pursue advanced training in the field of head and neck oncology and reconstructive surgery at the Medical University of South Carolina where he underwent fellowship training.

Dr. Houlton has been married to his wife Crystal for five years and has two young sons, Caleb and Everett.


Undergraduate Education: Texas A&M University, 2000

Medical School: University of Texas Medical Branch, 2004

Internship: University of Cincinnati Department of Otolaryngology, 2009

Residency: University of Cincinnati Department of Otolaryngology, 2013

Fellowship: Head and Neck Surgical Oncology and Microvascular Reconstruction, Medical University of South Carolina, 2014

Board Certification: Otolaryngology, 2014

Memberships: American Head and Neck Society, American Academy of Otolaryngology, Alpha Omega Alpha Honor Society

Awards and honors 

2018, 2017: Seattle Metropolitan Magazine Top Doctors
2018: National Cancer Institute Investigator
2018: Engineering in Health - Faculty Mentor Award 
2015: Distinguished Service for Model AAO-HNS Committee
2017-present: Consultant, AAO-HNS Microvascular Committee
2015-present: Washington State Representative, National Young Physicians Section of the AMA
2013-2017: American Academy of Otolaryngology Microvascular Committee
2013-2015: American Academy of Otolaryngology Endocrine Surgery Committee
2011: American Laryngological Association Research Award
2007: Alpha Omega Alpha Honor Society


Academic interests 


Dr. Houlton has clinical expertise in the treatment of cancers of the head and neck, as well as advanced microvascular reconstruction. He has special interest in the area of thyroid and parathyroid surgery, as well as salivary gland disease (including sialoendsocopy).


Dr. Houlton is passionate about clinical outcomes research related to microvascular reconstructive surgery, head and neck cancer treatment, and thyroid/parathyroid surgery.


Recent Publications

Tang AL, Aunins B, Chang K, Wang JC, Hagen M, Jiang L, Lee CY, Randle RW, Houlton JJ, Sloan D, Steward DL. A multi-institutional study evaluating and describing atypical parathyroid tumors discovered after parathyroidectomy., Laryngoscope Investig Otolaryngol 2022 Jun; 7(3):901-905

Moss SM, Ortiz-Hernandez M, Levin D, Richburg CA, Gerton T, Cook M, Houlton JJ, Rizvi ZH, Goodwin PC, Golway M, Ripley B, Hoying JB. A Biofabrication Strategy for a Custom-Shaped, Non-Synthetic Bone Graft Precursor with a Prevascularized Tissue Shell., Front Bioeng Biotechnol 2022 ; 10838415

Chalker C, Voutsinas JM, Wu QV, Santana-Davila R, Hwang V, Baik CS, Lee S, Barber B, Futran ND, Houlton JJ, Laramore GE, Liao JJ, Parvathaneni U, Martins RG, Eaton KD, Rodriguez CP. Performance status (PS) as a predictor of poor response to immune checkpoint inhibitors (ICI) in recurrent/metastatic head and neck cancer (RMHNSCC) patients., Cancer Med 2022 Mar

Pang J, Houlton JJ. Management of Malignant Salivary Gland Conditions., Surg Clin North Am 2022 Apr; 102(2):325-333

Robinson EM, Lam AS, Solomon I, Brady JS, Pang J, Faraji F, Houlton JJ, Futran ND, Barber BR. Trends in Positive Surgical Margins in cT1-T2 Oral Cavity Squamous Cell Carcinoma., Laryngoscope 2022 Feb